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Alveolar macrophages (AMs) represent a unique leukocyte population that responds to air-
borne irritants and microbes.This distinct microenvironment coordinates the maturation of
long-lived AMs, which originate from fetal blood monocytes and self-renew through mech-
anisms dependent on GM-CSF and CSF-1 signaling. Peripheral blood monocytes can also
replenish lung macrophages; however, this appears to occur in a stimuli specific manner.
In addition to mounting an appropriate immune response during infection and injury, AMs
actively coordinate the resolution of inflammation through efferocytosis of apoptotic cells.
Any perturbation of this process can lead to deleterious responses. In chronic obstruc-
tive pulmonary disease (COPD), there is an accumulation of airway macrophages that
do not conform to the classic M1/M2 dichotomy. There is also a skewed transcriptome
profile that favors expression of wound-healing M2 markers, which is reflective of a defi-
ciency to resolve inflammation. Endogenous mediators that can promote an imbalance in
inhibitory M1 vs. healing M2 macrophages are discussed, as they are the plausible mecha-
nisms underlying why AMs fail to effectively resolve inflammation and restore normal lung
homeostasis in COPD.
Keywords: alveolar macrophage, chronic obstructive pulmonary disease, efferocytosis, lung inflammation,
oxidative stress, resolution
INTRODUCTION
Macrophages are essential for pulmonary host defense through
their capacity to survey the exposed airways and regulate innate
and adaptive immunity. The pulmonary macrophage system con-
sists of several different populations that are found in anatomi-
cally distinct compartments, including the airways, alveolar spaces
[alveolar macrophages (AMs)], and resident lung tissue. AMs con-
stitute over 90% of the pulmonary macrophage population (1)
and have traditionally thought to originate from the bone marrow
(2). More recently, it has been shown that although AMs orig-
inate from fetal blood monocytes within the first week of life
via GM-CSF dependent mechanisms, maintenance of this pop-
ulation during homeostasis is dependent on their self-renewing
capacity (3). Once, developed, this lung macrophage pool is long-
lived in humans (2) in the absence of an inflammatory insult.
This finding has been replicated in mice, where there was approx-
imately 40% turnover of AMs over 1 year in the absence of an
insult (4). Hence, the macrophage lung population, particularly
during the steady state, is primarily sustained by the self-renewal
of pulmonary AMs through local proliferation (5). The local pro-
liferation of AMs during homeostatic repletion is dependent on
both GM-CSF and CSF-1, with no dependence on IL-4 signaling
(6). Both GM-CSF and M-CSF also control the proliferation and
survival of AMs (7). The differentiation of AMs is particularly
dependent on GM-CSF, where the leukocyte growth factor reg-
ulates essential functions including phagocytosis and surfactant
catabolism through the PU.1 transcription factor (8). This is con-
sistent with a unique airway environment that is associated with
high oxygen tension and high levels of GM-CSF.
Resident AMs are constantly encountering inhaled substances
due to their exposed position in the alveolar lumen. AMs are con-
sidered to be major effector cells in innate host defense against
inhaled irritants by virtue of their phagocytic ability (9). Therefore,
it is vital that resident AMs are kept in a relatively quiescent state
with active suppression of inflammation in response to harmless
antigens to prevent collateral damage to lung tissue (10). Although
AM exhibit microbicidal, tumoricidal, and parasiticidal activities
(9, 11), they are functionally less responsive than tissue-resident
macrophages. Relative to tissue macrophages, they display reduced
phagocytic capacity, reduced respiratory burst, and a diminished
capacity to present antigen to T cells (12–14). Under homeosta-
tic conditions, AMs are closely associated with alveolar epithelial
cells (AECs), and this in turn induces the expression of epithe-
lial restricted αvβ6 integrin that binds and activates latent TGFβ
(15). TGFβ can inhibit macrophage activation that is implicated
in alveolar wall destruction (15). Upon recognition of antigens
by TLRs, the rapid induction of actin polymerization promotes
AMs detachment from AECs (16). The subsequent production of
proteases by activated AMs then activates latent TGFβ, thereby
reinstating AMs to their resting state (16). This illustrates an
intricate mechanism of microenvironmental macrophage special-
ization to keep the macrophage response in check. AMs can also
produce TGFβ, which suppresses T cell activation and has been
shown to promote the emergence of T regulatory cells (17).
ROLE OF AMs IN INNATE HOST DEFENSE
In contrast to the self-renewing capacity of AMs during the steady
state, inflammatory and infective insults dramatically change the
www.frontiersin.org September 2014 | Volume 5 | Article 435 | 1
Vlahos and Bozinovski Alveolar macrophages in COPD
dynamics of local lung macrophages. Using chimeric mice, para-
biosis, and adoptive cellular transfer models, it has been established
that bone marrow-derived blood monocytes replenish the AM
pool during lethal irradiation (3). This is context specific, as inocu-
lation with influenza in mice, which dramatically depletes resident
AMs in a strain specific manner, led to restoration of this popula-
tion through self-renewal proliferative mechanisms (6). This infec-
tious model also promotes the substantial recruitment of blood
monocytes; however, the fate of monocyte-derived macrophages
has yet to be established in this setting. Using a similar approach,
LPS has been shown to restore lung macrophage numbers through
both local proliferation of resident macrophages and maturation
of recruited blood monocytes (18). Mouse blood monocytes can
be subdivided according to differential expression of chemokine
receptors and adhesion molecules that are involved in cell recruit-
ment. CCR2+Gr1hiCX3CR1lo is actively recruited to inflamed
tissues by virtue of their recognition of CCL2 (also known as MCP-
1) (19). Mouse monocytes that are CCR2+Gr1hiCX3CR1lo are
classified as pro-inflammatory but share morphological charac-
teristic and chemokine receptor patterns with the classical human
monocytes (CD14hiCD16−CX3CR1lo) (19). Monocyte-derived
macrophages can acquire distinct morphological and functional
properties as directed by the immunological microenvironment.
Alveolar macrophages coordinate antimicrobial defenses
through expression of receptors for immunoglobulin (FcR), com-
plement, β-glucan, mannose, and several types of scavenger recep-
tors that together facilitates phagocytosis (20). AMs generate reac-
tive nitrogen and oxygen intermediates involved in macrophage-
mediated defense against microbial infection (21, 22). Surfac-
tant protein A augments pathogen killing by AMs by stimu-
lating phagocytosis and production of reactive oxygen–nitrogen
intermediates (23). In addition, AMs can initiate recruitment of
inflammatory cells from pulmonary vasculature into the alve-
olar space. There are a number of studies that implicate AMs
as central effector cells in the production of pro-inflammatory
cytokines, which initiate the early phase of neutrophil influx in
response to acute lung injury caused by bacterial products (24, 25).
More recently, selective targeting strategies that ablate different
monocyte/macrophage populations have identified an important
role for peripheral blood monocytes. Ablation of CCR2hi mono-
cytes significantly reduced indices of acute lung injury (26). It
is plausible that AMs may actually play a role in limiting neu-
trophil influx by controlling MCP-1 production through AECs
(27). Furthermore, in a murine model of pneumococcal pneu-
monia, AMs depletion resulted in a failure to modulate the
inflammatory response with increased levels of pro-inflammatory
cytokines (28). AMs are also central regulators of the resolution of
inflammation through their ability to engulf apoptotic neutrophils
during the resolution phase (28, 29). The active phagocytosis
of dying cells by macrophages may also lead to the induction
of anti-inflammatory or suppressive properties in macrophages
as shown by the inhibition of IL-1β, IL-8, TNFα, and GM-CSF
production (30).
Alveolar macrophages are also indispensable for the clearance
of influenza infection in a viral strain-dependent manner in mice.
Here, it was established that the depletion of airway macrophages
was associated with more severe lung injury following inoculation
with BJx109, which is a viral strain that infects macrophages with
high efficiency (31). This is in contrast to the highly virulent
PR8 strain that poorly replicated in airway macrophages, sug-
gesting that avoidance of AM engagement may contribute to the
virulence of influenza strains (31). There is also the important
clinical complication of secondary bacterial infections following
a significant viral event, where AM function is likely to be com-
promised. In murine models of secondary bacterial infection, the
initial depletion of AMs as a consequence of influenza infection
rendered the host susceptible to Streptococcus pneumonia (Spn)
colonization and systemic invasion (32). The repletion of resident
AMs occurred 2 weeks after influenza, which resulted in the re-
establishment of early innate host protection to Spn (32). This
AM replenishment phase may represent a window of opportu-
nity for opportunistic respiratory pathogens such as Spn that take
advantage of this immunocompromised state. Interferon-γ pro-
duction during the recovery phase of a viral infection can also
inhibit lung anti-bacterial defenses. Mechanistically, it was shown
that viral-induced production of inteferon-γ caused downregu-
lation of the scavenger receptor MARCO, and neutralization of
interferon-γ prevented secondary pneumococcal infection (33).
Using MARCO-deficient mice, it has been established that expres-
sion of this scavenger receptor on AMs is critical for efficient
clearance of Spn from the lungs (34).
ROLE OF AMs IN CHRONIC OBSTRUCTIVE PULMONARY
DISEASE
There is a large body of evidence implicating AMs in the pathogen-
esis of Chronic Obstructive Pulmonary Disease (COPD). COPD is
a major global health problem and has been predicted to become
the third largest cause of death in the world by 2020 (35). Cigarette
smoking is the major cause of COPD and accounts for more than
95% of cases in industrialized countries (36), but other environ-
mental pollutants are important causes in developing countries
(37). COPD is “a disease state characterized by airflow limitation
that is not fully reversible.” The airflow limitation is usually pro-
gressive and associated with an abnormal inflammatory response
of lungs to noxious particles and gases (38). COPD encompasses
chronic obstructive bronchiolitis with fibrosis and obstruction of
small airways and emphysema with enlargement of airspaces and
destruction of lung parenchyma, loss of lung elasticity, and closure
of small airways. Most patients with COPD have all three patho-
logic conditions (chronic obstructive bronchiolitis, emphysema,
and mucus plugging), but the relative extent of emphysema and
obstructive bronchiolitis within individual patients can vary.
Studies have highlighted that macrophages play a pivotal role
in the pathophysiology of COPD (39). There is a marked increase
(5- to 10-fold) in the numbers of macrophages in airways, lung
parenchyma, bronchoalveolar lavage fluid (BALF), and sputum
in patients with COPD (40, 41). A morphometric analysis of
macrophage numbers in the parenchyma of patients with emphy-
sema showed a 25-fold increase in the numbers of macrophages
in the tissue and alveolar space compared to smokers with nor-
mal lung function (42). There is a positive correlation between
macrophage numbers in the airways and the severity of COPD
(43). In addition, a pathological role for macrophages has been
demonstrated, as the depletion of lung macrophages conferred
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protection against the development of emphysema in an exper-
imental model of COPD (44). Macrophages are activated by
cigarette smoke and other irritants to release inflammatory medi-
ators. AMs also secrete elastolytic enzymes (proteases), including
matrix metalloprotease (MMP)-2, MMP-9, MMP-12, cathepsin K,
L, and S in response to irritants and infection, which together are
responsible for destruction of lung parenchyma (36). In patients
with emphysema, there is an increase in BALF concentrations
and macrophage expression of MMP-1 and MMP-9 (45). There
is an increase in activity of MMP-9 in the lung parenchyma of
patients with emphysema (46). AMs from smokers with normal
lung function express more MMP-9 than those from non-smoking
healthy subjects (47), and there is an even greater increase in
cells from patients with COPD, which have enhanced elastolytic
activity (48).
Chronic obstructive pulmonary disease subjects can also be
very susceptible to bacterial colonization (49, 50) and exacerba-
tions that are commonly caused by respiratory infections of viral
and/or bacterial etiology (51). The frequent exacerbator pheno-
type has been reported, which is associated with a poorer quality of
life and increased systemic inflammation (52). Impaired AM func-
tion is central to high colonization rates and increased susceptibil-
ity to exacerbations observed in COPD. Chronic cigarette smoke
exposure is a major cause of COPD,which markedly depletes intra-
cellular GSH stores (53, 54). Oxidative stress leads to disruption of
GSH metabolism, which is considered as a key susceptibility fea-
ture of lung diseases (55). Excessive oxidative stress is particularly
deleterious to AM function, leading to a deficiency in phagocy-
tosis of bacteria (56) and efferocytosis of apoptotic cells (57).
Treatment with anti-oxidants such as procysteine can significantly
improve efferocytic function of AMs isolated from experimental
models of COPD (58). Impaired AM-mediated efferocytosis in
COPD can be particularly damaging in COPD as neutrophils are
persistently recruited into the airways. Cigarette smoke impairs
clearance of apoptotic cells through oxidant-dependent activation
of RhoA (59) and inhibition of Rac1 (60), leading to defective actin
polymerization normally required for efficient efferocytosis. The
inability to efficiently remove exhausted neutrophils has damag-
ing implications in COPD as accumulation of necrotic neutrophils
can lead to the indiscriminate release of granule protease pools
including neutrophil elastase. Neutrophil elastase localizes to lung
elastic fibers in emphysematic patients and degrades extracellular
matrix components (61) and can promote the release of mucins
through epidermal growth factor receptor (EGFR)-dependent
mechanisms (62). EGFR transactivation can also augment inflam-
matory responses initiated by rhinovirus infection (63). Reactive
free radicals also impair clearance mechanisms by directly causing
cytoskeletal instability and carbonyl modification of pseudopodia
(64–66). Macrophages also interact with carbonyl-adduct mod-
ified extracellular matrix proteins, which impair their ability to
clear apoptotic neutrophils (67).
In addition to oxidative post translational modification of the
host phagocytic machinery, the complex milieu within COPD air-
ways can alter the phenotype of highly plastic airway macrophages.
It is becoming increasing clear that different macrophage subpop-
ulations exist in the inflamed lung. Although the existence of such
populations is implicated in COPD, the importance of these sub-
populations is unknown (68). The ongoing characterization of
disease-associated macrophages clearly demonstrates that they do
not conform into the classic M1/M2 dichotomy and it is likely
that the inflammatory environment of the COPD airways drives
development of both M1 and M2 macrophages (58, 69). Indeed, it
has been shown that iNOS and arginase activity are concurrently
elevated in COPD airways. Specifically, elevated iNOS expression
has been observed in AMs of COPD patients, which increased with
severity of disease and during exacerbations (70–72). Of interest,
levels of exhaled nitric oxide (NO) are not elevated in stable COPD,
which may be consequential to increased production of superox-
ide that reacts with NO to generate the highly reactive nitrogen
species, peroxynitrite (73). In addition, arginase-1 is increased
in cigarette smoke exposure models (74), which will reduce l-
arginine availability to iNOS. Reduced l-arginine bioavailability
also stimulates iNOS to simultaneously produce NO and superox-
ide, which facilitates rapid formation of peroxynitrite (73). Consis-
tent with the concurrent existence of iNOS and arginase expressing
macrophages in COPD, nitrotyrosine (product of peroxynitrite)
levels have been shown to be increased in sputum macrophages
of COPD patients, which are negatively correlated with their
lung function (75). Hence, the relative ratio of iNOS express-
ing M1 macrophages and arginase expressing M2 macrophages
will be particularly important to the oxidative/nitrosative state of
the lung.
The relative balance between these polarization states can in
turn, have a profound impact on disease progression [reviewed
in Ref. (76)]. There is evidence for the reprograming of AMs as a
consequence of chronic smoke exposure that is associated with the
induction of a unique set of genes including MMP12 (77). There
is also evidence for the transcriptional skewing of AMs toward an
M2 gene profile in smokers with normal lung function that was
more evident in smokers who had progressed to develop COPD
(78). In this study, they also demonstrate the progressive down-
regulation of M1 genes (78), which would appear paradoxical
to the observation of increased expression of pro-inflammatory
mediators in COPD. Hence, there is a need to better define the rel-
ative contribution of M1 vs. M2 macrophages as there is emerging
evidence that both populations do concurrently exist in COPD
airways. Another important consideration in COPD is the inter-
action between macrophages and T cell subsets. Although it has
been broadly stated that T cells control the polarization state of
macrophages, macrophages can also potently regulate T cell biol-
ogy (79, 80). Since T cell subsets including CD8+ T cells, TH17, and
iBALT formation are implicated in COPD pathology, the role of
macrophages in regulating T cell biology remains to be elucidated.
The accumulation of M2 skewed airway macrophages may be
reflective of deficient resolution processes that normally switch
off inflammation and restore lung homeostasis. Since the stimu-
lation of non-phlogistic phagocytosis is essential to resolution of
inflammation, the oxidant-dependent impairment of efferocytic
clearance of damaged tissue may maintain M2 macrophages in
COPD. The induction of CD163 is commonly recognized as a
marker for M2-alternatively activated macrophages involved in
wound-healing (81, 82) and CD163 positive macrophages are
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highly prominent in the BAL compartment of current and ex-
smokers with COPD (83). CD163 may constitute a major defense
mechanism to protect the lung as it functions as a scavenger
receptor, which promotes degradation of HbHp complexes and
signaling that induces expression of heme-oxygenase-1 (HO-1)
(82). The persistence of HO-1 in COPD airways (84) is consis-
tent with an environment where there is excessive oxidative stress
and a deficiency in the resolution of inflammation. The mediators
that induce expression of M2 markers in COPD have not been
comprehensively characterized. Interleukin-10 (IL-10) is a potent
inducer of CD163 expression in human monocytes (85); how-
ever, there is some data to suggest that the level of IL-10 positive
macrophages is reduced in COPD (86). An alternate mediator that
has been shown to potently induce expression of CD163 in human
monocyte-derived macrophages is serum amyloid A (SAA) (87).
SAA is a major acute phase reactant that has now been shown to
be expressed in COPD lungs, where its levels correlated with neu-
trophilic inflammation (88). SAA is known to target the ALX/FPR2
receptor and oppose the actions of pro-resolving ligands such
as LipoxinA4 (88–90), which normally stimulate non-phlogistic
clearance pathways. In addition to CD163, SAA can also stimulate
the expression of the TH17 polarizing cytokines, IL-6, and IL-1β
in monocyte-derived macrophages, and neutralization of IL-17A
expression suppressed neutrophil airway inflammation stimulated
by SAA (91). Hence, the persistence of host defense mediators
such as SAA may maintain alternative macrophage populations in
COPD airways that not only express M2 markers of wound repair,
but also markers of acute inflammation.
CONCLUSION
In this review, the origin and maintenance of AMs and their
essential role in innate immunity to respiratory pathogens are
discussed. There is emerging evidence for the self-renewal of AMs
and lung tissue macrophages through mechanisms dependent on
GM-CSF and CSF-1 signaling. The role of peripheral monocytes
in replenishing lung macrophages appear to be context specific,
as radiation-induced lung injury stimulates monocytic replenish-
ment, whereas influenza infection replenishes AMs through local
proliferation of resident macrophages. In diseases such as COPD
where there is an accumulation of airway macrophages, the relative
contribution of monocyte versus local proliferation of mature AM
populations remains to be determined. Lineage tracing of mono-
cytes/macrophages in experimental models of COPD will inform
on the origin of macrophages associated with disease pathology.
Alveolar macrophages coordinate the efficient clearance of
inhaled irritants and microbes to resolve inflammation. In addi-
tion, AMs display efferocytic activity to clear damaged tissue and
cells following injury and infection. In COPD, the persistence of
inflammation and the inability to efficiently clear damaged tissue
and exhausted immune cells such as neutrophils may be due to
excessive oxidative stress that impairs the phagocytic capacity of
AMs. Airway macrophages in COPD also display a unique phe-
notype that is associated with the induction of M2-related genes,
which are likely to be upregulated in response to local tissue dam-
age (Figure 1). The maintenance of this subpopulation may also
contribute to deleterious remodeling in COPD. Thus, there is a
FIGURE 1 | COPD alveolar macrophage. Cigarette smoke, oxidative
stress, and the airway inflammatory microenvironment have a direct effect
on alveolar macrophage (AM) phenotype in COPD that leads to the
emergence of M1 and M2 populations. The ratio of these macrophages will
govern the pathological processes in COPD. M1 macrophages will further
drive inflammation and oxidative stress. Excessive oxidative stress impairs
resolution mechanisms including macrophage-mediated phagocytosis and
efferocytosis, which leads to colonization and exacerbations in COPD. In
addition, the emergence of M2 macrophages can contribute to deleterious
lung remodeling/damage through increased expression of M2-related
genes and excessive protease (MMP-9, -12) production.
need to better characterize distinct AM populations present in
COPD and their relative contribution to disease pathology, as their
highly plastic nature offer a therapeutic opportunity to reprogram
macrophages to facilitate restoration of lung homeostasis.
REFERENCES
1. van oud Alblas AB, van Furth R. Origin, kinetics, and characteristics of
pulmonary macrophages in the normal steady state. J Exp Med (1979)
149(6):1504–18. doi:10.1084/jem.149.6.1504
2. Thomas ED, Ramberg RE, Sale GE, Sparkes RS, Golde DW. Direct evidence
for a bone marrow origin of the alveolar macrophage in man. Science (1976)
192(4243):1016–8. doi:10.1126/science.775638
3. Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, et al. Alveo-
lar macrophages develop from fetal monocytes that differentiate into long-lived
cells in the first week of life via GM-CSF. J Exp Med (2013) 210(10):1977–92.
doi:10.1084/jem.20131199
4. Maus UA, Janzen S, Wall G, Srivastava M, Blackwell TS, Christman JW, et al.
Resident alveolar macrophages are replaced by recruited monocytes in response
to endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol (2006)
35(2):227–35. doi:10.1165/rcmb.2005-0241OC
5. Tarling JD, Lin HS, Hsu S. Self-renewal of pulmonary alveolar macrophages:
evidence from radiation chimera studies. J Leukoc Biol (1987) 42(5):443–6.
6. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-
resident macrophages self-maintain locally throughout adult life with mini-
mal contribution from circulating monocytes. Immunity (2013) 38(4):792–804.
doi:10.1016/j.immuni.2013.04.004
7. Lin HS, Lokeshwar BL, Hsu S. Both granulocyte-macrophage CSF and
macrophage CSF control the proliferation and survival of the same subset of
alveolar macrophages. J Immunol (1989) 142(2):515–9.
Frontiers in Immunology | Molecular Innate Immunity September 2014 | Volume 5 | Article 435 | 4
Vlahos and Bozinovski Alveolar macrophages in COPD
8. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC.
GM-CSF regulates alveolar macrophage differentiation and innate immunity
in the lung through PU.1. Immunity (2001) 15(4):557–67. doi:10.1016/S1074-
7613(01)00218-7
9. Franke-Ullmann G, Pfortner C, Walter P, Steinmuller C, Lohmann-Matthes ML,
Kobzik L. Characterization of murine lung interstitial macrophages in compar-
ison with alveolar macrophages in vitro. J Immunol (1996) 157(7):3097–104.
10. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is
associated with an increase in pulmonary immune response in mice. J Exp Med
(1989) 170(2):499–509. doi:10.1084/jem.170.2.499
11. Prokhorova S, Lavnikova N, Laskin DL. Functional characterization of intersti-
tial macrophages and subpopulations of alveolar macrophages from rat lung.
J Leukoc Biol (1994) 55(2):141–6.
12. Holt PG. Inhibitory activity of unstimulated alveolar macrophages on T-
lymphocyte blastogenic response. Am Rev Respir Dis (1978) 118(4):791–3.
13. Hoidal JR, Schmeling D, Peterson PK. Phagocytosis, bacterial killing, and metab-
olism by purified human lung phagocytes. J Infect Dis (1981) 144(1):61–71.
doi:10.1093/infdis/144.1.61
14. Blumenthal RL, Campbell DE, Hwang P, DeKruyff RH, Frankel LR, Umetsu
DT. Human alveolar macrophages induce functional inactivation in antigen-
specific CD4 T cells. J Allergy Clin Immunol (2001) 107(2):258–64. doi:10.1067/
mai.2001.112845
15. Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G,
et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes
Mmp12-dependent emphysema. Nature (2003) 422(6928):169–73. doi:10.1038/
nature01413
16. Takabayshi K, Corr M, Hayashi T, Redecke V, Beck L, Guiney D, et al. Induc-
tion of a homeostatic circuit in lung tissue by microbial compounds. Immunity
(2006) 24(4):475–87. doi:10.1016/j.immuni.2006.02.008
17. Coleman MM, Ruane D, Moran B, Dunne PJ, Keane J, Mills KH. Alveolar
macrophages contribute to respiratory tolerance by inducing FoxP3 expression
in naive T cells. Am J Respir Cell Mol Biol (2013) 48(6):773–80. doi:10.1165/
rcmb.2012-0263OC
18. Duan M, Li WC, Vlahos R, Maxwell MJ, Anderson GP, Hibbs ML. Distinct
macrophage subpopulations characterize acute infection and chronic inflam-
matory lung disease. J Immunol (2012) 189(2):946–55. doi:10.4049/jimmunol.
1200660
19. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two princi-
pal subsets with distinct migratory properties. Immunity (2003) 19(1):71–82.
doi:10.1016/S1074-7613(03)00174-2
20. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S.
Macrophage receptors and immune recognition. Annu Rev Immunol (2005)
23:901–44. doi:10.1146/annurev.immunol.23.021704.115816
21. Nathan CF, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicro-
bial activity. Curr Opin Immunol (1991) 3(1):65–70. doi:10.1016/0952-7915(91)
90079-G
22. Fantone JC, Ward PA. Role of oxygen-derived free radicals and metabo-
lites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982)
107(3):395–418.
23. Hickman-Davis JM, O’Reilly P, Davis IC, Peti-Peterdi J, Davis G, Young KR, et al.
Killing of Klebsiella pneumoniae by human alveolar macrophages. Am J Physiol
Lung Cell Mol Physiol (2002) 282:L944–56. doi:10.1152/ajplung.00216.2001
24. Hashimoto S, Pittet JF, Hong K, Folkesson H, Bagby G, Kobzik L, et al. Deple-
tion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas
airspace infections. Am J Physiol (1996) 270(5 Pt 1):L819–28.
25. Maus UA, Koay MA, Delbeck T, Mack M, Ermert M, Ermert L, et al. Role of
resident alveolar macrophages in leukocyte traffic into the alveolar air space
of intact mice. Am J Physiol Lung Cell Mol Physiol (2002) 282(6):L1245–52.
doi:10.1152/ajplung.00453.2001
26. Dhaliwal K, Scholefield E, Ferenbach D, Gibbons M, Duffin R, Dorward DA,
et al. Monocytes control second-phase neutrophil emigration in established
lipopolysaccharide-induced murine lung injury. Am J Respir Crit Care Med
(2012) 186(6):514–24. doi:10.1164/rccm.201112-2132OC
27. Beck-Schimmer B, Schwendener R, Pasch T, Reyes L, Booy C, Schimmer RC.
Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced
lung injury. Respir Res (2005) 6:61. doi:10.1186/1465-9921-6-61
28. Knapp S, Leemans JC, Florquin S, Branger J, Maris NA, Pater J, et al. Alve-
olar macrophages have a protective antiinflammatory role during murine
pneumococcal pneumonia. Am J Respir Crit Care Med (2003) 167(2):171–9.
doi:10.1164/rccm.200207-698OC
29. Cox G, Crossley J, Xing Z. Macrophage engulfment of apoptotic neu-
trophils contributes to the resolution of acute pulmonary inflammation
in vivo. Am J Respir Cell Mol Biol (1995) 12(2):232–7. doi:10.1165/ajrcmb.12.2.
7865221
30. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM.
Macrophages that have ingested apoptotic cells in vitro inhibit proinflamma-
tory cytokine production through autocrine/paracrine mechanisms involving
TGF-beta, PGE2, and PAF. J Clin Invest (1998) 101(4):890–8. doi:10.1172/
JCI1112
31. Tate MD, Pickett DL, van Rooijen N, Brooks AG, Reading PC. Critical role
of airway macrophages in modulating disease severity during influenza virus
infection of mice. J Virol (2010) 84(15):7569–80. doi:10.1128/JVI.00291-10
32. Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages
during influenza infection facilitates bacterial superinfections. J Immunol (2013)
191(3):1250–9. doi:10.4049/jimmunol.1300014
33. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by
interferon-gamma during recovery from influenza infection. Nat Med (2008)
14(5):558–64. doi:10.1038/nm1765
34. Arredouani M, Yang Z, Ning Y, Qin G, Soininen R, Tryggvason K, et al. The
scavenger receptor MARCO is required for lung defense against pneumo-
coccal pneumonia and inhaled particles. J Exp Med (2004) 200(2):267–72.
doi:10.1084/jem.20040731
35. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med (1998)
4(11):1241–3. doi:10.1038/3218
36. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary dis-
ease: molecular and cellular mechanisms. Eur Respir J (2003) 22(4):672–88.
doi:10.1183/09031936.03.00040703
37. Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke expo-
sure and risk for obstructive airways disease among women. Chest (1996)
109(1):115–9. doi:10.1378/chest.109.1.115
38. Pauwels RA,Buist AS,Calverley PM,Jenkins CR,Hurd SS,Committee GS. Global
strategy for the diagnosis, management, and prevention of chronic obstruc-
tive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive
lung disease (GOLD) workshop summary. Am J Respir Crit Care Med (2001)
163(5):1256–76. doi:10.1164/ajrccm.163.5.2101039
39. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am
J Respir Crit Care Med (1999) 160(5 Pt 2):S29–32. doi:10.1164/ajrccm.160.
supplement_1.9
40. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, et al. Inflamma-
tory cells and mediators in bronchial lavage of patients with chronic obstructive
pulmonary disease. Eur Respir J (1998) 12(2):380–6. doi:10.1183/09031936.98.
12020380
41. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8
and tumor necrosis factor-alpha in induced sputum from patients with chronic
obstructive pulmonary disease or asthma. Am J Respir Crit Care Med (1996)
153(2):530–4. doi:10.1164/ajrccm.153.2.8564092
42. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, et al. Ampli-
fication of inflammation in emphysema and its association with latent adenovi-
ral infection. Am J Respir Crit Care Med (2001) 164(3):469–73. doi:10.1164/
ajrccm.164.3.2007149
43. Di Stefano A, Capelli A, Lusuardi M, Balbo P,Vecchio C, Maestrelli P, et al. Sever-
ity of airflow limitation is associated with severity of airway inflammation in
smokers. Am J Respir Crit Care Med (1998) 158(4):1277–85. doi:10.1164/ajrccm.
158.4.9802078
44. Beckett EL, Stevens RL, Jarnicki AG, Kim RY, Hanish I, Hansbro NG, et al. A
new short-term mouse model of chronic obstructive pulmonary disease identi-
fies a role for mast cell tryptase in pathogenesis. J Allergy Clin Immunol (2013)
131(3):752–62. doi:10.1016/j.jaci.2012.11.053
45. Finlay GA, O’Driscoll LR, Russell KJ, D’Arcy EM, Masterson JB, FitzGerald
MX, et al. Matrix metalloproteinase expression and production by alveolar
macrophages in emphysema. Am J Respir Crit Care Med (1997) 156(1):240–7.
doi:10.1164/ajrccm.156.1.9612018
www.frontiersin.org September 2014 | Volume 5 | Article 435 | 5
Vlahos and Bozinovski Alveolar macrophages in COPD
46. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix
metalloproteinase-mediated extracellular matrix protein degradation in human
pulmonary emphysema. Lab Invets (1998) 78(9):1077–87.
47. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance
of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from
alveolar macrophages in cigarette smokers. Regulation by interleukin-10.
Am J Respir Crit Care Med (2000) 162(4 Pt 1):1355–60. doi:10.1164/ajrccm.
162.4.9910097
48. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, et al.
Release and activity of matrix metalloproteinase-9 and tissue inhibitor of
metalloproteinase-1 by alveolar macrophages from patients with chronic
obstructive pulmonary disease. Am J Respir Cell Mol Biol (2002) 26(5):602–9.
doi:10.1165/ajrcmb.26.5.4685
49. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, et al. Bacterial infection in
chronic obstructive pulmonary disease. A study of stable and exacerbated out-
patients using the protected specimen brush. Am J Respir Crit Care Med (1995)
152(4 Pt 1):1316–20. doi:10.1164/ajrccm.152.4.7551388
50. Pela R, Marchesani F, Agostinelli C, Staccioli D, Cecarini L, Bassotti C, et al. Air-
ways microbial flora in COPD patients in stable clinical conditions and during
exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis (1998)
53(3):262–7.
51. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G,
et al. Infections and airway inflammation in chronic obstructive pulmonary dis-
ease severe exacerbations. Am J Respir Crit Care Med (2006) 173(10):1114–21.
doi:10.1164/rccm.200506-859OC
52. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al.
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl
J Med (2010) 363(12):1128–38. doi:10.1056/NEJMoa0909883
53. Birrell MA, Wong S, Catley MC, Belvisi MG. Impact of tobacco-smoke on key
signaling pathways in the innate immune response in lung macrophages. J Cell
Physiol (2008) 214(1):27–37. doi:10.1002/jcp.21158
54. Muller T, Gebel S. The cellular stress response induced by aqueous extracts of
cigarette smoke is critically dependent on the intracellular glutathione concen-
tration. Carcinogenesis (1998) 19(5):797–801. doi:10.1093/carcin/19.5.797
55. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung
inflammation. Eur Respir J (2000) 16(3):534–54. doi:10.1034/j.1399-3003.2000.
016003534.x
56. Marti-Lliteras P, Regueiro V, Morey P, Hood DW, Saus C, Sauleda J, et al.
Nontypeable Haemophilus influenzae clearance by alveolar macrophages is
impaired by exposure to cigarette smoke. Infect Immun (2009) 77(10):4232–42.
doi:10.1128/IAI.00305-09
57. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. Smok-
ing alters alveolar macrophage recognition and phagocytic ability: implications
in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2007)
37(6):748–55. doi:10.1165/rcmb.2007-0025OC
58. Hodge S, Matthews G, Mukaro V, Ahern J, Shivam A, Hodge G, et al. Ciga-
rette smoke-induced changes to alveolar macrophage phenotype and function
are improved by treatment with procysteine. Am J Respir Cell Mol Biol (2011)
44(5):673–81. doi:10.1165/rcmb.2009-0459OC
59. Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao YQ, Keith RL, et al.
Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent
activation of RhoA. Am J Respir Crit Care Med (2009) 179(11):1011–21.
doi:10.1164/rccm.200807-1148OC
60. Minemetsu N, Blumental-Perry A, Shapiro SD. Cigarette smoke inhibits engulf-
ment of apoptotic cells by macrophages through inhibition of actin rearrange-
ment. Am J Respir Cell Mol Biol (2011) 44(4):474–82. doi:10.1165/rcmb.2009-
0463OC
61. Damiano VV, Tsang A, Kucich U, Abrams WR, Rosenbloom J, Kimbel P, et al.
Immunolocalization of elastase in human emphysematous lungs. J Clin Invest
(1986) 78(2):482–93. doi:10.1172/JCI112600
62. Shao MX, Nadel JA. Neutrophil elastase induces MUC5AC mucin produc-
tion in human airway epithelial cells via a cascade involving protein kinase C,
reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol (2005)
175(6):4009–16. doi:10.4049/jimmunol.175.6.4009
63. Liu K, Gualano RC, Hibbs ML, Anderson GP, Bozinovski S. Epidermal growth
factor receptor signaling to Erk1/2 and STATs control the intensity of the
epithelial inflammatory responses to rhinovirus infection. J Biol Chem (2008)
283(15):9977–85. doi:10.1074/jbc.M710257200
64. Banan A, Zhang Y, Losurdo J, Keshavarzian A. Carbonylation and disassem-
bly of the F-actin cytoskeleton in oxidant induced barrier dysfunction and its
prevention by epidermal growth factor and transforming growth factor alpha in
a human colonic cell line. Gut (2000) 46(6):830–7. doi:10.1136/gut.46.6.830
65. Smerjac SM, Bizzozero OA. Cytoskeletal protein carbonylation and degra-
dation in experimental autoimmune encephalomyelitis. J Neurochem (2008)
105(3):763–72. doi:10.1111/j.1471-4159.2007.05178.x
66. Bozinovski S, Vlahos R, Zhang Y, Lah LC, Seow HJ, Mansell A, et al. Carbonyla-
tion caused by cigarette smoke extract is associated with defective macrophage
immunity. Am J Respir Cell Mol Biol (2011) 45(2):229–36. doi:10.1165/rcmb.
2010-0272OC
67. Kirkham PA, Spooner G, Rahman I, Rossi AG. Macrophage phagocytosis of
apoptotic neutrophils is compromised by matrix proteins modified by cigarette
smoke and lipid peroxidation products. Biochem Biophys Res Commun (2004)
318(1):32–7. doi:10.1016/j.bbrc.2004.04.003
68. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD (2004)
1(1):59–70. doi:10.1081/COPD-120028701
69. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation.
Nat Rev Immunol (2008) 8(12):958–69. doi:10.1038/nri2448
70. Agusti AG, Villaverde JM, Togores B, Bosch M. Serial measurements of exhaled
nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur
Respir J (1999) 14(3):523–8. doi:10.1034/j.1399-3003.1999.14d34.x
71. Bhowmik A, Seemungal TA, Donaldson GC, Wedzicha JA. Effects of exacer-
bations and seasonality on exhaled nitric oxide in COPD. Eur Respir J (2005)
26(6):1009–15. doi:10.1183/09031936.05.00047305
72. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled
nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care
Med (1998) 157(3 Pt 1):998–1002. doi:10.1164/ajrccm.157.3.97-05009
73. Maarsingh H, Pera T, Meurs H. Arginase and pulmonary diseases. Naunyn
Schmiedebergs Arch Pharmacol (2008) 378(2):171–84. doi:10.1007/s00210-008-
0286-7
74. Gebel S, Gerstmayer B, Kuhl P, Borlak J, Meurrens K, Muller T. The kinetics of
transcriptomic changes induced by cigarette smoke in rat lungs reveals a specific
program of defense, inflammation, and circadian clock gene expression. Toxicol
Sci (2006) 93(2):422–31. doi:10.1093/toxsci/kfl071
75. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive
nitrogen species production in chronic obstructive pulmonary disease airways.
Am J Respir Crit Care Med (2000) 162(2 Pt 1):701–6. doi:10.1164/ajrccm.162.2.
9908132
76. Mills CD, Ley K. M1 and M2 macrophages: the chicken and the egg of immunity.
J Innate Immun (2014) 6(6). doi:10.1159/000364945
77. Woodruff PG, Koth LL, Yang YH, Rodriguez MW, Favoreto S, Dolganov GM,
et al. A distinctive alveolar macrophage activation state induced by cigarette
smoking. Am J Respir Crit Care Med (2005) 172(11):1383–92. doi:10.1164/rccm.
200505-686OC
78. Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey BG, O’Connor TP,
et al. Smoking-dependent reprogramming of alveolar macrophage polariza-
tion: implication for pathogenesis of chronic obstructive pulmonary disease.
J Immunol (2009) 183(4):2867–83. doi:10.4049/jimmunol.0900473
79. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages
and the Th1/Th2 paradigm. J Immunol (2000) 164(12):6166–73. doi:10.4049/
jimmunol.164.12.6166
80. Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev
Immunol (2012) 32(6):463–88. doi:10.1615/CritRevImmunol.v32.i6.10
81. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine
system in diverse forms of macrophage activation and polarization. Trends
Immunol (2004) 25(12):677–86. doi:10.1016/j.it.2004.09.015
82. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-
of-all-trades and potential target for cell-directed therapy. Mol Immunol (2010)
47(7–8):1650–60. doi:10.1016/j.molimm.2010.02.008
83. Kunz LI, Lapperre TS, Snoeck-Stroband JB, Budulac SE, Timens W, van Wijn-
gaarden S, et al. Smoking status and anti-inflammatory macrophages in bron-
choalveolar lavage and induced sputum in COPD. Respir Res (2011) 12:34.
doi:10.1186/1465-9921-12-34
84. Dolinay T, Choi AM, Ryter SW. Heme oxygenase-1/CO as protective media-
tors in cigarette smoke-induced lung cell injury and chronic obstructive pul-
monary disease. Curr Pharm Biotechnol (2012) 13(6):769–76. doi:10.2174/
138920112800399338
Frontiers in Immunology | Molecular Innate Immunity September 2014 | Volume 5 | Article 435 | 6
Vlahos and Bozinovski Alveolar macrophages in COPD
85. Williams L, Jarai G, Smith A, Finan P. IL-10 expression profiling in human
monocytes. J Leukoc Biol (2002) 72(4):800–9.
86. Takanashi S, Hasegawa Y, Kanehira Y, Yamamoto K, Fujimoto K, Satoh K,
et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD
and in smokers. Eur Respir J (1999) 14(2):309–14. doi:10.1183/09031936.99.
14230999
87. Anthony D, McQualter JL, Bishara M, Lim EX, Yatmaz S, Seow HJ,
et al. SAA drives proinflammatory heterotypic macrophage differentiation in
the lung via CSF-1R-dependent signaling. FASEB J (2014). doi:10.1096/fj.14-
250332
88. Bozinovski S, Uddin M,Vlahos R, Thompson M, McQualter JL, Merritt AS, et al.
Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung
inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S
A (2012) 109(3):935–40. doi:10.1073/pnas.1109382109
89. Bozinovski S, Anthony D, Anderson GP, Irving LB, Levy BD, Vlahos R. Treat-
ing neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution
pathways. Pharmacol Ther (2013) 140(3):280–9. doi:10.1016/j.pharmthera.
2013.07.007
90. El Kebir D, Jozsef L, Khreiss T, Pan W, Petasis NA, Serhan CN, et al. Aspirin-
triggered lipoxins override the apoptosis-delaying action of serum amyloid
A in human neutrophils: a novel mechanism for resolution of inflammation.
J Immunol (2007) 179(1):616–22. doi:10.4049/jimmunol.179.1.616
91. Anthony D, Seow HJ, Uddin M, Thompson M, Dousha L, Vlahos R, et al. Serum
amyloid A promotes lung neutrophilia by increasing IL-17A levels in the mucosa
and gammadelta T cells. Am J Respir Crit Care Med (2013) 188(2):179–86.
doi:10.1164/rccm.201211-2139OC
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 22 July 2014; paper pending published: 18 August 2014; accepted: 26 August
2014; published online: 10 September 2014.
Citation: Vlahos R and Bozinovski S (2014) Role of alveolar macrophages
in chronic obstructive pulmonary disease. Front. Immunol. 5:435. doi:
10.3389/fimmu.2014.00435
This article was submitted to Molecular Innate Immunity, a section of the journal
Frontiers in Immunology.
Copyright © 2014 Vlahos and Bozinovski. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org September 2014 | Volume 5 | Article 435 | 7
